

Canada Insulin Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 75 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Canada Insulin Delivery Devices Market size is estimated at USD 1.27 billion in 2024, and is expected to reach USD 1.45 billion by 2029, growing at a CAGR of 2.67% during the forecast period (2024-2029).

According to Diabetes Canada 2021, since the beginning of the COVID-19 pandemic, studies have shown that diabetes was one of the major comorbidities associated with developing severe COVID-19-related adverse outcomes and mortality. Adults with diabetes who contracted COVID-19 were at higher risk of developing adult respiratory distress syndrome, pneumonia, excessive uncontrolled inflammation responses, and a hypercoagulable state.

Early reports depicted in-hospital death from COVID-19 to be 2.85 times higher in adults living with diabetes compared to patients without diabetes. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe and improved inpatient glycemic outcomes and played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.

Diabetes is a chronic condition characterized by high blood glucose levels caused by the inability to produce or use insulin effectively. The main types of diabetes are type-1 diabetes and type-2 diabetes. For a patient with type 1 diabetes, insulin therapy is important for replacing the insulin the body doesn't produce. People with type-2 diabetes or gestational diabetes need insulin therapy if other treatments, such as diabetes medications and other lifestyle changes, cannot keep blood glucose levels within the desired range.

Diabetes treatment aims to maintain healthy blood glucose levels to prevent short- and long-term complications, such as cardiovascular disease, kidney disease, blindness, and lower limb amputation. Furthermore, patients attempting to control their

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily insulin or insulin pump therapy injections.

Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate insulin administration. Medtronic recently launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintain insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves insulin's physical and chemical stability and reliability of infusion site performance and reduces the risk of an infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is tested and approved to keep insulin stable and safely used for up to 7 days.

Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.

Canada Insulin Delivery Devices Market Trends

Rising Diabetes Prevalence in Canada is anticipated to boost the market studied.

The diabetes prevalence in Canada is expected to rise by about 2.7% over the forecast period.

In the current year, according to Diabetes Canada, more than 5.7 million Canadians are living with diagnosed diabetes (type-1 or type-2 diabetes); however, 11.7 million Canadians are living with diabetes or prediabetes, a condition that, if left unmanaged, can develop into type-2 diabetes. Diabetes also costs the healthcare system USD 30 billion annually to treat people with diabetes.

Diabetes care can be most effective when combined with an education program that incorporates instruction for people with diabetes on healthy behavior changes in response to blood glucose values and for healthcare providers on how to adjust antihyperglycemic medications in response to blood glucose readings. As part of this education, people with diabetes should receive instruction on how and when to perform self-monitoring, record the results in an organized manner, the meaning of various blood glucose levels, and how behavior and actions affect blood glucose results.

The Canadian Diabetes Strategy is a national partnership that includes the provinces and territories, many national health organizations and interest groups, and Aboriginal communities nationwide. The purpose of the Canadian Diabetes Strategy is to articulate and establish effective diabetes prevention and control strategies for Canada. With access to the collective knowledge and experience of its various partners, the Canadian Diabetes Strategy is well-positioned to determine the needs and gaps and ensure that resources are deployed accordingly.

Therefore, the studied market is anticipated to grow over the analysis period due to rising prevalence and increasing awareness through government initiatives.

The Insulin Cartridges in Reusable Pens Segment holds the highest market share in the Canada Insulin Delivery Devices Market in the current year

The Insulin Cartridges in Reusable Pens Segment holds the highest market share in the Canada Insulin Delivery Devices Market in the current year and is expected to register a CAGR of about 2.9% in the market over the forecast period.

Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run. Due to the increasing demand for

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

insulin cartridges, most insulin device manufacturers have produced reusable insulin pens compatible with various insulin manufacturers' cartridges. Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate insulin administration. Some pens are smart insulin pens that easily connect to an app on the phone to monitor blood sugar levels and remind when to take the next insulin dose.

The World Health Assembly Resolution 2022 recommended the integration of prevention and treatment of diabetes into primary health services, developing pathways for a substantial increase in access to insulin, promoting convergence and harmonizing regulatory requirements for diabetes medicines and technologies, and improving diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.

Thus, the abovementioned factors are expected to drive segment growth over the forecast period.

Canada Insulin Delivery Devices Industry Overview

The Canadian Insulin Delivery Devices Market is semi-consolidated due to major companies operating globally and regionally, namely Medtronic, Insulet Corporation, Novo Nordisk, Sanofi, Eli Lilly and Company, etc., and other regional players.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.3 Market Restraints

4.4 Porter's Five Forces Analysis

4.4.1 Bargaining Power of Suppliers

4.4.2 Bargaining Power of Consumers

4.4.3 Threat of New Entrants

4.4.4 Threat of Substitute Products and Services

4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation

5.1 Type

5.1.1 Insulin Pumps

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1.1 Insulin Pump Device
- 5.1.1.2 Insulin Infusion Sets
- 5.1.1.3 Insulin Reservoirs
- 5.1.2 Insulin Syringes
- 5.1.3 Disposable Insulin Pens
- 5.1.4 Insulin Cartridges in Reusable Pens
- 5.1.5 Insulin Jet Injectors

6 MARKET INDICATORS

- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

- 7.1 Company Profiles
 - 7.1.1 Medtronic
 - 7.1.2 F. Hoffmann-La Roche
 - 7.1.3 Insulet Corporation
 - 7.1.4 Tandem Diabetes Care
 - 7.1.5 Ypsomed Holding AG
 - 7.1.6 Sanofi
 - 7.1.7 Becton, Dickinson and Company
 - 7.1.8 Eli Lilly and Company
 - 7.1.9 Novo Nordisk
- 7.2 Company Share Analysis
 - 7.2.1 Medtronic
 - 7.2.2 Novo Nordisk
 - 7.2.3 Eli Lilly and Company
 - 7.2.4 Other Company Share Analyses

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Canada Insulin Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 75 pages | Mordor Intelligence

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-06-25
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com